Role of cyclin D1 amplification and expression in vulvar carcinomas.
Standard
Role of cyclin D1 amplification and expression in vulvar carcinomas. / Choschzick, Matthias; Hess, Stephan; Tennstedt, Pierre; Holst, Frederik; Bohlken, Hiltila; Gieseking, Frederike; Mahner, Sven; Wölber, Linn; Simon, Ronald; Sauter, Guido.
in: HUM PATHOL, Jahrgang 43, Nr. 9, 9, 2012, S. 1386-1393.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Role of cyclin D1 amplification and expression in vulvar carcinomas.
AU - Choschzick, Matthias
AU - Hess, Stephan
AU - Tennstedt, Pierre
AU - Holst, Frederik
AU - Bohlken, Hiltila
AU - Gieseking, Frederike
AU - Mahner, Sven
AU - Wölber, Linn
AU - Simon, Ronald
AU - Sauter, Guido
PY - 2012
Y1 - 2012
N2 - Cyclin D1 (CCND1) belongs to the family of D-type cyclins involved in cell cycle progression, transcriptional regulation, and cell migration. CCND1 was found to be amplified and overexpressed in a variety of cancers, including some vulvar carcinoma cell lines. To determine the relationship of CCND1 copy number changes and CCND1 protein expression with clinicopathologic features and prognosis, 183 vulvar carcinomas were analyzed on a tissue microarray. Amplification was observed in 32 (22.4%) vulvar cancer specimens and was statistically related to the presence of regional lymph node metastases (P < .001). Detectable CCND1 expression was found in 139 (83.2%) of vulvar carcinomas, and 76 (45.5%) exhibited a moderate or strong expression. Increased levels of CCND1 expression were significantly related to higher patient age (P = .013), positive pN category (P = .004), and negative human papillomavirus status (P < .001). Basaloid as well as verrucous, warty-type, and mixed vulvar carcinomas showed lower CCND1 expression levels than keratinizing or nonkeratinizing tumors (P < .001 and P = .032, respectively). Elevated CCND1 expression levels and amplification of the CCND1 gene were closely connected in the present analysis (P < .001). Patient prognosis was independent from CCND1 amplification status and expression level (P = .57 each). In conclusion, CCND1 is amplified and overexpressed in a substantial proportion of vulvar carcinomas and associated with the occurrence of locoregional lymph node metastases, especially in human papillomavirus-negative tumors.
AB - Cyclin D1 (CCND1) belongs to the family of D-type cyclins involved in cell cycle progression, transcriptional regulation, and cell migration. CCND1 was found to be amplified and overexpressed in a variety of cancers, including some vulvar carcinoma cell lines. To determine the relationship of CCND1 copy number changes and CCND1 protein expression with clinicopathologic features and prognosis, 183 vulvar carcinomas were analyzed on a tissue microarray. Amplification was observed in 32 (22.4%) vulvar cancer specimens and was statistically related to the presence of regional lymph node metastases (P < .001). Detectable CCND1 expression was found in 139 (83.2%) of vulvar carcinomas, and 76 (45.5%) exhibited a moderate or strong expression. Increased levels of CCND1 expression were significantly related to higher patient age (P = .013), positive pN category (P = .004), and negative human papillomavirus status (P < .001). Basaloid as well as verrucous, warty-type, and mixed vulvar carcinomas showed lower CCND1 expression levels than keratinizing or nonkeratinizing tumors (P < .001 and P = .032, respectively). Elevated CCND1 expression levels and amplification of the CCND1 gene were closely connected in the present analysis (P < .001). Patient prognosis was independent from CCND1 amplification status and expression level (P = .57 each). In conclusion, CCND1 is amplified and overexpressed in a substantial proportion of vulvar carcinomas and associated with the occurrence of locoregional lymph node metastases, especially in human papillomavirus-negative tumors.
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Prognosis
KW - Tumor Markers, Biological/genetics/metabolism
KW - Gene Amplification
KW - Carcinoma/genetics/metabolism/pathology
KW - Cyclin D1/genetics/metabolism
KW - Lymphatic Metastasis/genetics/pathology
KW - Vulva/metabolism/pathology
KW - Vulvar Neoplasms/genetics/metabolism/pathology
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Prognosis
KW - Tumor Markers, Biological/genetics/metabolism
KW - Gene Amplification
KW - Carcinoma/genetics/metabolism/pathology
KW - Cyclin D1/genetics/metabolism
KW - Lymphatic Metastasis/genetics/pathology
KW - Vulva/metabolism/pathology
KW - Vulvar Neoplasms/genetics/metabolism/pathology
M3 - SCORING: Journal article
VL - 43
SP - 1386
EP - 1393
JO - HUM PATHOL
JF - HUM PATHOL
SN - 0046-8177
IS - 9
M1 - 9
ER -
